Autoimmune Treatment Market Report 2026

Autoimmune Treatment Market Overview

• Autoimmune Treatment market size has reached to $8.63 billion in 2025 • Expected to grow to $16.53 billion in 2030 at a compound annual growth rate (CAGR) of 13.9% • Growth Driver: Increasing Healthcare Expenditures Boosting The Autoimmune Treatment Market • Market Trend: Innovative Clinical Trial Platforms Transform Autoimmune Treatment Market • North America was the largest region in 2025.

What Is Covered Under Autoimmune Treatment Market?

Autoimmune treatment refers to the management and care of a patient for the purpose of combating an autoimmune disease or disorder. This is a type of condition in which one's immune system starts attacking its own body cells. The autoimmune treatment is used to treat autoimmune diseases. The main types of products in autoimmune treatment are consumables and assay kits, instruments, and services. Consultation refers to seeking assistance from another physicians or health care professionals for diagnostic studies, therapeutic interventions, or other services. Diagnosis is the process of identifying the nature of an illness or other problem by examination of the signs and symptoms. The main service types include consultation and diagnosis, therapy and monitoring, and drug development that involve several diseases such as rheumatoid arthritis, systemic lupus erythematosus, sjögren’s syndrome, thyroiditis, scleroderma, and others. The main drug classes include anti-inflammatory, anti-hyperglycemics, NSAIDs, interferons, and others. The main end user are clinical laboratories, hospitals, and others.

What Is The Autoimmune Treatment Market Growth Forecast?

The autoimmune treatment market size is expected to see rapid growth in the next few years. It will grow to $16.53 billion in 2030 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to increasing investment in novel biologics development, rising demand for personalized autoimmune therapies, expansion of digital monitoring and follow-up care, growing focus on reducing long-term disease complications, increased research into immune system modulation. Major trends in the forecast period include increasing adoption of biologic therapies, rising use of targeted immunomodulators, growing integration of long-term disease management programs, expansion of personalized treatment regimens, enhanced focus on combination drug therapies.

What Is The Driver Of The Autoimmune Treatment Market?

The rise in healthcare expenditures is expected to propel the growth of the autoimmune treatment market going forward. Health expenditures refer to all costs associated with providing health services, family planning activities, nutrition programs, and emergency help with a focus on health. A rise in healthcare expenditure would result in the development of more effective therapies and medical technologies for autoimmune treatment. For instance, according to the economic forecast from the Office for Budget Responsibility (OBR) and Treasury, the UK's planned health expenditure is projected to increase to £192 billion ($244.43 billion) in 2024/25, up from £182 billion ($231.70 billion) in 2022/23. Similarly, the National Health Expenditures Accounts (NHEA) from KFF, a US-based independent health policy research organization, indicate that health spending in the United States is anticipated to grow by 5% from 2023 to 2024, reaching $4.9 trillion. Therefore, the rise in healthcare expenditures is driving the growth of the autoimmune treatment industry.

Key Players In The Global Autoimmune Treatment Market

Major companies operating in the autoimmune treatment market are Abbott Laboratories, Amgen Inc., Eli Lilly and Company, Pfizer Inc., F Hoffmann-La Roche AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Biogen Idec Inc., GSK PLC, Genentech Inc., AbbVie Inc., Celgene Corporation, Gilead Sciences Inc., Merck & Co. Inc., Novartis International AG, Sanofi SA, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Alexion Pharmaceuticals Inc., AnaptysBio Inc., Apellis Pharmaceuticals Inc., Arena Pharmaceuticals Inc., Aurinia Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Cabaletta Bio Inc., ChemoCentryx Inc., Corbus Pharmaceuticals Holdings Inc., CSL Limited

Global Autoimmune Treatment Market Trends and Insights

Major companies operating in the autoimmune treatment market are increasing their focus on introducing innovative clinical trial platforms to gain a competitive edge in the market. Innovative clinical trial platforms in autoimmune treatment leverage advanced technologies and personalized approaches to enhance efficacy, safety, and patient outcomes. For instance, in August 2023, the Scleroderma Research Foundation, a US-based non-profit organization, launched the CONQUEST trial platform. The CONQUEST program aims to advance research and treatments for scleroderma, a rare autoimmune disease that affects connective tissues. It addresses critical issues in clinical development and enables advances in scleroderma therapeutics. The CONQUEST platform clinical trial is the first of its kind in rare autoimmune diseases, and it is designed to quickly evaluate potential treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) as well as global SSc outcomes, including some focused on skin and other aspects of the disease.

What Are Latest Mergers And Acquisitions In The Autoimmune Treatment Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired DICE Therapeutics, Inc. for $2.4 billion. The acquisition broadens Lilly's immunology product range by incorporating DICE's innovative oral therapeutic candidates, including oral IL-17 inhibitors currently undergoing clinical development for the treatment of chronic immunological disorders. DICE Therapeutics, Inc. is a US-based pharmaceutical company that focuses on developing novel oral therapies for autoimmune and inflammatory conditions.

What Defines the Autoimmune Treatment Market?

The autoimmune treatment includes revenues earned by entities by providing immunosuppressive therapy, biological treatment, immuno-suppressing medications services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Autoimmune Treatment Market Report 2026?

The autoimmune treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the autoimmune treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.